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The formation of new vessels, angiogenesis, is essential for
tumour growth and metastasis (Folkman, 1990). Angiogenic
process includes retraction of pericytes, protease dissolution of 
the capillary basement membrane and extracellular matrix, and
through modulation of specific adhesion molecules (Bischoff,
1995), endothelial cell (EC) migration. Sprouts are formed which
elongate and fuse to form a network of interconnecting loops
(Paweletz and Knierim, 1989). Capillary differentiation, including
the formation of an irregular basement membrane composed of
abnormal ratios of the normal constituents then occurs, before
initiation of the blood flow (Blood and Zetter, 1990; Paku and
Paweletz, 1991).
LH39 is an antibody to a basement membrane epitope located in
the lamina lucida (Almeida et al, 1992a). Normal basement
membranes are complex, highly compartmentalized structures
composed of three major structural zones (lamina lucida, lamina
densa and lamina reticularis) (Laurie and Leblond, 1985). Tumour
vasculature is known to consist of an irregular basement
membrane, composed of variable amounts of fibronectin, laminin
and collagen, depending on the maturation status of the capillary
(Paku and Paweletz, 1991). Such structural defects of the
microvasculature together with the functional effects of various
angiogenic factors account for the permeability of the tumour-
associated endothelium. LH39 has recently been demonstrated to
be present in the basement membranes of small veins and capil-
laries within the stroma of normal human organs, but was absent in
newly formed vessels of several pathological conditions (e.g.
ulcers, granulomas) and in cancer (Almeida et al, 1992a, 1992b).
LH39 was also found to be absent in large and medium-sized
arteries and veins of normal, inflammatory or neoplastic tissues
(Almeida et al, 1992b). This is of additional interest, since other
basement membrane compounds, like laminin and collagen type
IV are known to be expressed in vessels of all sizes.
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Summary Angiogenesis, the formation of new vessels, has been demonstrated to be an indicator of prognosis in breast cancer patients. The
extent of differentiation of the tumour vessels may affect access of peripheral white cells and egress or invasion of tumour cells. This has not
been assessed in relation to tumour microvessel density or other variables and may be a marker of vascular remodelling. LH39 is a
monoclonal antibody recognizing an epitope located at the lamina lucida of mature small veins and capillaries but not in newly formed
vessels. To study vascular differentiation in breast tumours, we examined the vascular maturation index (VMI) in 12 normal and 50 breast
carcinomas and this was correlated with different clinicopathological variables including angiogenesis. Mature vessels were defined by
staining with antibodies to both LH39 and to CD31, using double immunohistochemistry, whereas immature vessels stained only for CD31.
VMI was defined as the % fraction of mature vessels (LH39-positive) / total number of vessels (CD31-positive). The VMI was significantly
higher in normal (54–68.5%; median 66.5%) than in tumours (0–47%; median 8.8%) (P = 0.0005). There was a significant inverse correlation
between the tumour VMI and nodal status (Fisher’s exact test, P = 0.01) and between high VMI and low thymidine phosphorylase (TP)
expression (Mann–Whitney U-test, P = 0.01). No significant association between VMI and tumour size, oestrogen receptor, epidermal growth
factor receptor, grade, angiogenesis, patient age, or E-selectin was seen. There was a significant reduction in relapse-free survival (P = 0.01)
with high angiogenesis. These findings show that the VMI gives new information on the mechanism of tumour angiogenesis independently
from microvessel quantitation, there is a wide variation in the differentiation of tumour vasculature but the degree of capillary differentiation is
not associated with quantitative angiogenesis. The VMI identifies a subset of patients who have a high chance of regional node involvement.
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DOI: 10.1054/ bjoc.1999.1010, available online at http://www.idealibrary.com on The formation of a new basement membrane usually comes as a
late event, following migration and proliferation of ECs within the
sprout (Sholley et al, 1984). The establishment of a mature base-
ment membrane has been shown to be accompanied with restricted
EC proliferation, something which is mostly associated with the
presence of pericytes in the vessel wall (Orlidge and D’Amore,
1987). Hence, although EC proliferation is required for angio-
genesis, it is the migration and remodelling of the existing tissue
vascular supply which establish the functional vasculature within
the tumour (Fox et al, 1993).
To study further the importance of remodelling the existing
vessels for tumour angiogenesis, we have examined the vascular
maturation index (VMI) of normal and neoplastic breast tissues by
measuring the proportion of the total tumour vasculature high-
lighted by the EC marker CD31 that also express the basement
membrane epitope recognized by the mouse monoclonal antibody
LH39 (Almeida et al, 1992a, 1992b). Thus this ratio will give the
proportion of vessels in individual tumours that are undergoing
remodelling and are still in an immature state. Clearly ECs
produced by proliferation will also be incorporated into the remod-
elled vasculature.
Cell adhesion molecules (CAMs) and their ligands play a major
role in metastasis and angiogenesis (Denton et al, 1992; Nelson 
et al, 1994). The expression of selectins on endothelium at the
tumour periphery, where angiogenesis is most active, may play a
direct role in tumour angiogenesis. In vitro evidence suggests that
selectins are involved in capillary morphogenesis and that ligand
binding to selectins of endothelial cells alters their morphology
and function (Luscinskas and Lawler, 1994; Bischoff, 1995).
Thymidine phosphorylase (TP), an enzyme originally isolated
from platelets and also known as platelet-derived endothelial cell
growth factor (PDECGF), has been shown to exhibit a chemotactic
and mitogenic capacity on endothelial cells in several angiogenic
model systems (Haraguchi et al, 1994; Moghaddam et al, 1995;
Folkman, 1996). In breast carcinomas up-regulation of TP has
been observed (Fox et al, 1996). Therefore, we have also evaluated
the expression of E-selectin and TP, and have compared all these
measurements to conventional clinicopathological variables and
quantitative angiogenesis.
MATERIALS AND METHODS
Patients and tumours
Twelve normal breast samples (from reduction mammoplasties)
and 50 consecutive primary breast tumours were collected from
Cellular Pathology, John Radcliffe Hospital, Oxford, UK. Twelve
out of the 50 tumours also included adjacent normal breast tissue.
The specimens were snap-frozen in liquid nitrogen and stored at
–70°C. Cryostat sections (7-mm thick) were fixed in acetone for 
10 min at room temperature, left to dry overnight and either
stained immediately or stored at –20°C until required. Formalin-
fixed, paraffin-embedded tissue samples from the same breast
tumours were also cut in 4-mm thick sections and mounted onto
silane-coated slides for CD31 immunohistochemical analysis. The
clinicopathological characteristics of patients and tumours are
detailed in Table 1. Patients were treated with lumpectomy (n =
35) or simple mastectomy (n = 15); tamoxifen was given to those ³
50 years of age or oestrogen receptor (ER)-positive and <50 years
old. In patients < 50 years old, adjuvant cyclophosphamide,
methotrexate and 5-fluorouracil (CMF) was administered if
tumours were node-positive, or ER-negative and/or ³ 3 cm.
Patients ³ 50 years with ER-negative, node-positive tumours also
received CMF. Twelve patients received chemotherapy, 20 tamox-
ifen and 18 both. Follow-up (median 70 months (range 10–86
months)) was 3-monthly for 18 months, and 6-monthly until 
3 years.
Immunohistochemistry
The primary antibodies used were for PECAM/CD31, JC70A
(Dako, UK); E-selectin/CD62, E1.2 B6 (ascites dil.1/500) from D
Haskard, London, UK; lamina lucida antigen, LH39 (supernatant)
from I Leigh, London, UK; TP/PG44c (supernatant) from KC
Gatter, Oxford, UK. For double-labelling, a three-step, indirect
avidin–biotin peroxidase complex (ABC) technique was first
performed using LH39, before an alkaline phosphatase anti-alka-
line phosphatase (APAAP) staining procedure with JC70 was
performed as described below. The specificity of all staining was
confirmed by replacing the primary antibodies with an irrelevant
isotype antibody.
LH39/CD31
Seven-micrometre cryostat sections were incubated with LH39
overnight in a moist chamber at 40°C. Secondary antibody,
biotinylated goat anti-mouse immunoglobulin (Dako; K492) was
applied for 20 min, followed by incubation with streptavidin
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Table 1 Clinicopathological characteristics of patients and tumours
Age, years
Median (range) 55 (32–79)
< 50 16
³ 50 34
Surgical treatment
Lumpectomy 35
Simple mastectomy 15
Adjuvant treatment
Chemotherapy 12
Tamoxifen 20
Both 18
Lymph nodes, neg/pos 31/19
Tumour size, cm
Median (range) 2.4 (0.3–5.5)
≤ 21 2
> 2 37
Histology
Ductal 35
Lobular 4
Others 11
Grade (ductal)
I3
II 11
III 21
ER fmol mg–1
Median (range) 12 (0–314)
< 10 23
³ 10 27
EGFR fmol mg–1
Median (range) 9.2 (0–710)
< 20 36
³ 20 14
Survival follow-up, months
Median (range) 70 (10–86)
Deaths/Recurrences 12/17biotinylated horseradish peroxidase for another 20 min.
Peroxidase reaction was developed using diaminobenzidine
tetrahydrochloride (DAB; Sigma). Slides were then incubated
with JC70 (CD31) for 1 h at room temperature before sequential
application of anti-mouse immunoglobulin (Dako; Z259, at 1/50
dilution) and APAAP complex for 30 min each. This step was
repeated twice (second and third incubations) for a further 10 min
each to enhance the intensity of the final staining. The APAAP
reaction was visualized using new fuchsin (Dako; K596) and
slides were weakly counterstained with haematoxylin and
mounted in aqueous medium. Three 5-min washings between
incubations in Tris-buffered saline (TBS) pH 7.2 was performed.
E-selectin
Immunohistochemistry for E-selectin was performed on the same
cryostat sections (multiwell slides each including four serial sections
were used), stained with 1.2B6, using the streptavidin–biotin horse-
radish peroxidase–DAB technique (Fox et al, 1995a). A semi-quan-
titative analysis was used for assessment of E-selectin expression, as
previously described (Fox et al, 1995a).
TP
A standard peroxidase ABC method using DAB as chromogen,
was performed to visualize TP staining, with PG44c antibody as
primary, as previously described (Fox et al, 1995b). Assessment of
TP expression was based on both the intensity and extent of
staining of either: (a) the tumour cells, or (b) cancer cells and
stroma cells (overall TP). Cases were considered TP-positive, 
if more than 25% of cells displayed moderate staining, as this 
cut-point has previously been found to be significant in predicting
survival in node-positive breast tumours treated with CMF, with
high TP expressors showing improved survival (Fox et al, 1996).
ER and EGFR
These were determined by enzyme-linked immunosorbent assay
(ELISA) technique (Abbott Laboratories, USA) and ligand
binding of 125I-EGF respectively. Tumours were considered posi-
tive when ER ³ 10 fmol mg–1 cytosolic and EGFR ³ 20 membrane
protein respectively (Fox et al, 1994).
Quantitation of tumour angiogenesis
A 25-point Chalkley eypiece graticule (Chalkley, 1943) was used
to count vascular hot spots identified by scanning the tumour at
´40–100 by two observers over a conference microscope.
Microvessels were defined as any immunoreactive EC(s) separate
from adjacent microvessels. Vessels within the sclerotic body of
the tumour were not included (Weidner et al, 1991). Counting at
´250 magnification (0.155 mm2) was then performed by rotating
the graticule in the eyepiece to where the maximum number of
dots overlay stained vessels. The mean of the three counts was
used in the subsequent analysis and tumours with counts > 7 were
considered high vascularity. Tumours with counts of less than 7
were considered as low (0–4) and median (5–6) vascularity.
However, low and median vascularity were included in the same
group, since previous studies have shown the validity of this cate-
gorization (Fox et al, 1995c). Chalkley counts were determined
without knowledge of patient outcome (Fox et al, 1995c).
VMI
All vessels were stained with anti-CD31 antibody but only a
subset stained for LH39. The median number of LH39-positive
vessels per field, and the number of LH39-positive vessels in the
‘hot spot’ area (as indicators of maturation), were counted and
used for statistical analysis. VMI was defined as the percentage of
LH39-stained to CD31-stained vessels, both quantified in the
same double-stained section. The index was derived by counting
the total number of double (LH39+CD31) and single (CD31)-
stained vessels in each tumour section. Thus, the index was LH39-
positive vessels/total CD31-positive vessels ´ 100 to express as a
percentage. Counting was done throughout the section (at ´250
magnification), with the Chalkley graticule maintained in one
position (the average not the maximal number of vessels in the
tissue section was counted). Vessel counting (the criteria for which
are described above) was determined independently by two
observers. The counts were split by tertiles and the upper third was
used as the cut-off for categorical and survival analyses (Fox et al,
1995c, 1995d).
Statistical analysis
These were performed using Stata Release 3.1 (Stata Corporation,
TX, USA). Fisher’s exact test was used to examine the relationship
between categorical variables, and dependent logistic regression
with backward analysis for interaction between variables. A non-
parametric Mann–Whitney U-test was used to compare relation-
ship between TP expression (overall or tumour TP) as categorical
variable, and VMI as a continuous tumour variable. Paired or
unpaired ranked sums were used for paired or unpaired data
respectively. The log-rank test was used to perform univariate
survival analyses.
RESULTS
Positive labelling for LH39 was detected in all normal and
neoplastic tissues examined. The staining was evident in the base-
ment membranes of small vessels and epithelial basement
membranes. Details of the staining pattern are described below.
LH39 expression in normal breast (reduction
mammoplasty vs tissue adjacent to tumour)
In the 12 examined cases from reduction mammoplasties, LH39
labelled the majority of endothelial basement membranes of small
veins and capillaries. The distribution and the intensity of staining
for LH39 in normal breast microvasculature was generally
homogenous. The VMI in normal breast ranged from 54 to 68.5%
(median 66.5%). The staining of vessels with antibodies to both
CD31 and LH39 antigen is shown in Figure 1 A and B.
In the 12 cases of normal breast tissue close to invasive tumour,
the median VMI was lower than in reduction mammoplasties
(52.5%, range 18–75%), and this difference was significant (P =
0.007), unpaired ranked sums, Figure 2, C vs D). Basement
membranes surrounding breast ducts and lobules were also
strongly positive for LH39.
LH39 expression in breast carcinomas
In the 50 breast carcinomas examined, VMI was assessed either in
the three ‘hot spot’ areas (previously selected for angiogenesis
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British Journal of Cancer (2000) 82(4), 844–851 © 2000 Cancer Research CampaignLH39 as indicator of vascular maturation in breast cancer 847
British Journal of Cancer (2000) 82(4), 844–851 © 2000 Cancer Research Campaign
assessment) and throughout the tumour. The mean hot spot VMI
was 6.1 ± 8, which was lower than the VMI for the whole tumour
area, mean 11.4 ± 9,  P = 0.0001. Linear regression analysis
showed that the hot spot MRI correlated with overall VMI 
(r = 0.061, P = 0.0001). The latter was considered as more repre-
sentative in defining vessel maturation in the whole tumour and was
subsequently used in the statistical analysis. However, the same
analyses for correlation with pathological variables and outcome
were analysed using hot spot VMI and none were significant.
Whole area VMI in breast carcinomas ranged from 0 to 47%
(median 8.8%), which was significantly lower than that observed
in the 12 normal breast cases (range 54–68.5%; median 66.5%, 
P < 0.0005, unpaired ranked sums) and the 12 cases of normal
breast besides tumour (range 18–75%; median 52.5%, P < 0.0005,
paired ranked sums). The staining for tumour vessels with anti-
bodies to CD31 and LH39 antigen is shown in Figure 1, C and D.
An analysis was performed comparing VMI between all 50 cancer
cases (Figure 1A), the 12 cancer cases with adjacent normal breast
(Figure 1B), the same cases with normal breast adjacent to inva-
sive tumour (Figure 1C) and 12 normal breast cases taken from
reduction mammoplasties (Figure 1D). The difference in VMI
between tumour and reduction mammoplasty breast was again
highly significant (Figure 1A or B vs C, P < 0.0001, unpaired
ranked sums, Figure 2), as was the difference in the tumour and
paired adjacent normal tissue (B vs C, P < 0.0001, Figure 2).
LH39-positive vessels were identified throughout the tumour body
in all examined cases. However, focal differences in the distribu-
tion of LH39-positive vessels were observed in three cases at the
invasive tumour edge. In those cases, the concentration of LH39-
positive vessels at the invasive edge, was higher than that observed
in the remaining tumour area and appeared to represent entrapped
residual normal tissue. LH39 expression was evident in all tumour
A
CD
B
Figure 1 Single immunohistochemical staining with either CD31 (APAAP) or LH39 (ABC). Normal breast (A and B) stained with CD31 (red) and LH39 (brown)
showing most vessels to be stained with occasional vessels being only CD31-positive. Invasive breast carcinomas stained for and CD31 (red, C) and LH39
(brown, D) showing most vessels are CD31 single-stained
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Figure 2 Scattergram of vascular maturation index (VMI) in all 50 cancer
cases (A), in 12 cancer cases with adjacent normal breast tissue (B), in 12
cases with normal breast adjacent to tumour (C), in 12 cases with normal
reduction mammoplasty tissue (D). The index represents the ratio of mature
vessels expressing LH39 antigen over total vessels detected by CD31
expressionepithelial basement membranes, in a similar pattern to that
observed in normal breast. Only in some cases with extensive
disruption of the basement membranes was focal or occasional
LH39 expression seen.
Expression of E-selectin on breast tumour endothelium
A significant proportion of the tumour endothelial cells also
showed positive staining for E-selectin. Hence, 14/50 cases were
negative, 21/50 were positive and 15/50 cases presented strong
positivity for E-selectin. Expression of E-selectin was not
restricted to a particular vessel type but was observed in the
endothelial cells of arterioles, venules and small capillaries.
However, in 14/36 cases showing immunoreactivity with 
E-selectin the staining was more prominent at the tumour
periphery. In three cases a weak labelling for E-selectin was
observed within the neoplastic element of the tumour.
TP expression
The usual pattern of immunoreactivity for TP/PD-ECGF was both
nuclear and cytoplasmic but occasionally only one of these was
present. Immunoreactivity was heterogenous, occasionally focal,
and often up-regulated at the infiltrating tumour edge.
Immunostaining was frequent in the stroma, tumour-associated
macrophages and endothelial cells. Tumour cells were positive for
TP/PD-ECGF in 24/37 cases, while overall TP/PD-ECGF posi-
tivity was detected in 22/37 examined cases with breast carci-
nomas.
Relationship of VMI expression to other tumour
variables and survival analysis
VMI expression was analysed either as a continuous or as a cate-
gorical variable. On splitting VMI into thirds (cut-off points 6%
and 13% LH39-positive vessels) we categorized VMI in breast
carcinomas as high, medium or low. The Fisher exact tests
performed to see the relationship of VMI to different tumour vari-
ables revealed a relationship of high VMI to negative lymph node
status (P = 0.01), but not to other prognostic variables (Table 2).
Dependent logistic regression confirmed the only significant
factor relating to node involvement was VMI (P = 0.007, Table 3).
Also stratifying by tertiles 11/19 low VMI (< 6%) were node-posi-
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Table 2 Contingency tables comparing VMI with the clinicopathological
characteristics of patients
VMI
Low High P-value
Age (years)
< 50 10 6
≤ 50 24 10 0.75
Lymph nodes
Negative 17 14
Positive 17 2 0.01
Grade
I/II 8 5
III 14 4 0.43
Tumour size
≤ 2c m 6 6
> 2 cm 27 10 0.17
E-selectin
Negative 23 13
Positive 11 3 0.5
Angiogenesis
≤ 72 6 1 2
> 7 7 4 0.75
ERa
< 10 14 9
≤ 10 20 7 0.37
TP (tumour)
Negative 7 6
Positive 12 12 0.09
TP (overall)
Negative 3 12
Positive 12 10 0.01
EGFRa
< 20 25 10
³ 20 9 6 0.52
afmol mg–1 protein.
Table 3 Dependent logistic regression on 50 patients examining
relationship between positive lymph node status and other clinicopathological
variables
Variable Odds ratio 95% CI P-value
Angiogenesis > 7; ≤ 7 1.13 (0.2–5.9) 0.9
ERa ³ 10; < 10 1.6 (0.3–7.6) 0.56
EGFRa ³ 20; < 20 0.9 (0.16–5.1) 0.9
Age ³ 50; < 50 0.33 (0.1–2.2) 0.26
TP (overall) positive; negative 0.8 (0.15–3.2) 0.8
Size > 2 cm; ≤ 2 3.2 (0.5–19.6) 0.2
VMI high; medium; low 0.2 (0.1–0.6) 0.007
CI, confidence intervals. afmol mg–1 protein.
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Figure 3 Correlation of vascular maturation index (VMI) and angiogenesis
(as detected by Chalkley score, CS) with nodal (N) involvement. High VMI
correlates significantly with negative lymph node status (N0)tive, 6/15 medium VMI (< 13%) were node-positive, and only
2/16 high VMI (> 13%) were node-positive (P = 0.02, Fisher’s
exact test). Continuous variable analysis also confirmed that VMI
significantly correlated with node involvement. Cases with N0 had
a VMI of 13.5 + 10.6, whilst cases with N1 had a VMI of 8.5 + 6.9
(Figure 3, P = 0.05).
The Mann–Whitney U-test revealed a significant correlation
between high VMI (analysed as continuous variable) and low
(negative) overall TP expression (as categorical variable, P = 0.01,
Table 2), but not for tumour cell TP expression.
The univariate analysis performed to see significance of each
tumour variable in predicting relapse, revealed significance only
for angiogenesis (P = 0.01) but not for any VMI category.
Similarly, only angiogenesis and lymph node status were found to
have significance in predicting survival (P = 0.02 and 0.002
respectively). Variables combining angiogenesis with VMI cate-
gories were also produced, and VMI was found to have no impact
in defining subgroups with different prognosis in low or high
angiogenesis cases. Cases with low angiogenesis had a statistically
better prognosis compared to cases with high angiogenesis no
matter what the VMI was.
DISCUSSION
Using a double immunohistochemical labelling technique for EC
and basement membrane markers, using a basement membrane
component absent from vessels actively involved in neovascular-
ization (Almeida et al, 1992a, 1992b), we have demonstrated that
the degree of vascular maturation in normal and neoplastic breast
tissue varies widely.
Normal breast tissues, like other mature normal tissues, have a
fully developed vessel network and a quiescent endothelial cell
phenotype (Fox et al, 1993; Vartanian and Weidner, 1994).
However, the proportion of poorly differentiated vessels observed
in the normal breast tissues in this study, which consist largely of
reduction mammoplasties, suggests that angiogenesis is occurring
to a greater extent in physiologically normal adult tissues, than
indicated by endothelial labelling. Thus, although EC proliferation
is not characteristic of angiogenesis in normal breast, an angio-
genic phenotype defined by the presence of LH39-negative
(immature) vesels, indicating a remodelling process, might still
occur in normal breast. In the case of breast tissue, the process may
be part of the more general tissue alterations, which occur during
cyclical hormonal release. Indeed there is increasing evidence that
oestrogens effect several steps of the angiogenic process (Morales
et al, 1995; Schnaper et al, 1996), including mediation of cytokine-
induced adhesion molecule expression in endothelial cells
(Caulin-Glazer et al, 1996), molecules important in the remodel-
ling process.
We have suggested previously, based on a relatively low EC
proliferation index in breast carcinomas (mean 2.2%), that EC
remodelling might be an important mechanism by which human
tumours establish a blood supply (Fox et al, 1993). The findings in
the present study show a high proportion of poorly differentiated
vessels throughout the tumour as well as at the growing edge
where dividing EC are present (Fox et al, 1993). Thus, VMI may
represent the aggregate of new vessels produced by both division
and remodelling. The VMI in the microvessel hot spots was even
lower than in the rest of the tumour, reflecting the remodelling of
dividing ECs and confirming these areas as the most angiogenic.
There was a significant correlation between the hot spot VMI and
total VMI suggesting that either the rest of the vasculature devel-
oped from the hot spots or that there may be separate vascular
remodelling factors acting throughout the tumour in addition to
those regulating proliferation at the hot spots. The remodelling of
tumour vasculature continues after its formation (Folkman, 1997),
reflecting a potential stratagem by which a tumour might match its
blood supply to its growing demands. Furthermore, the increase in
VMI between tumour, normal near tumour and normal breast is in
accordance with the notion that angiogenesis is tightly suppressed
in normal tissues but might be stimulated by genetic changes in
apparent normal tissues (Deng et al, 1996). Alternatively, this may
be an effect of soluble mediators acting in a paracrine mechanism.
Although no significant association between VMI and quantita-
tive angiogenesis, either in the area assessed for vessel differentia-
tion or in the remainder of the tumour (hot spot method) was
observed, the VMI measures a different aspect of angiogenesis to
vessel number, since it gives the proportion of tumour vessels
being remodelled. This is supported by the observed significant
inverse association between a low VMI (high vascular remodel-
ling) and positive lymph node status. The association of an imma-
ture, poorly differentiated vasculature may also be representative
of the lymphatic vessels at the periphery of the tumour. This would
facilitate regional spread. Also, the immature vessels themselves
may contribute via proteases to local invasion of tumour. The asso-
ciation with nodal status is also in accordance with the possibility
that leaky immature vessels are more likely to facilitate tumour
cell escape into adjacent lymphatics, a process that would be
retarded in more mature vessels.
Although several earlier studies (Bosari et al, 1992; Weidner et
al, 1992) found an association of high microvessel density with
lymph node involvement, a similar number of studies has found no
association, as reported here (Kato et al, 1999; Toi et al, 1994; Van
Hoef et al, 1993). The reasons are unclear but probably reflect that
there is not a direct relation of the route of lymph node spread to
the vasculature, although both processes reflect an aggressive
phenotype. There is substantial heterogeneity in breast cancer so
that either meta-analysis or much larger studies are needed to
resolve this.
High VMI was found to associate with low TP expression. TP,
although not a classic growth factor, has been shown to be both
chemotactic and mitogenic for endothelial cells and angiogenic in
several model systems (Haraguchi et al, 1994; Moghaddam et al,
1995; Folkman, 1996). Therefore, low expression of a mito-
genic/angiogenic factor, such as TP, may indicate a less aggressive
tumour phenotype. This would possibly facilitate the establish-
ment of a well differentiated/mature tumour vasculature, which by
turn associates with good prognostic features, such as regional
lymph node negativity. No significant association between VMI
and other clinicopathological variables was observed. E-selectin
expression was more prominent at the tumour periphery, an area
where angiogenesis is most active (Fox et al, 1993), consistent
with a reported role in capillary morphogenesis (Nguyen et al,
1993; Kaplanski et al, 1994; Luscinskas and Lawler, 1994;
Bischoff, 1995). However, the pathways in this study do not
appear to be simultaneously expressed.
A tumour is considered to have ‘switched’ to an angiogenic
phenotype when it alters the balance of angiogenic stimulators and
inhibitors, thereby gaining the capacity to establish a blood supply.
Tumour angiogenesis is not an ordered process and individual
LH39 as indicator of vascular maturation in breast cancer 849
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(Warren, 1979; Lin et al, 1984; Skinner et al, 1995). Thus, the
number of tumour vessels alone will only give one aspect of a
tumour’s ability to complete the complex angiogenic programme.
Although low VMI was associated with regional node spread,
tumours that have acquired the ability to form mature vessels, 
i.e. have a high VMI similar to normal tissues, might be those
tumours with a more effective blood supply. Thus, VMI might not
only give an index of the proportion of vessels produced by cell
division and remodelling (angiogenic index), but might also give
an indication as to the function of such vessels. Indeed, particular
vascular patterns in lung carcinomas (Pezella et al, 1996), and
ocular melanomas (Folberg et al, 1993), which similarly might
reflect different qualitative angiogenic phenotypes, have been
shown to be associated with differences in prognosis.
Currently, tumour angiogenesis is measured by estimating the
number of immunohistochemically identified vessels in angio-
genic hot spots (Fox, 1997), however, not all studies have
confirmed the utility of this technique. Furthermore, the efficiency
of the tumour vasculature will be determined not only by the
number but by the quality of the vessels generated. These limita-
tions have encouraged the evaluation of other indirect measures of
tumour angiogenesis, such as serum growth factor levels from
cancer-bearing patients (Nguyen et al, 1994). The concept of an
angiogenic profile encompassing several angiogenic pathways
might be more useful and measures of capillary maturation should
be considered as a potential part. This might become more impor-
tant with the advent of anti-angiogenic agents directed against
particular processes involved in vascular remodelling, such as EC
migration, cell–matrix interactions and secretion of basement
membrane (Ingber and Folkman, 1988; Maragoudakis et al, 1988;
Nicosia and Bonano, 1991; Sakamoto et al, 1991; Kibbey et al,
1992; Grant et al, 1994).
These observations are also relevant to the efficacy of vascular
targeting (Nicosia and Bonano, 1991). This type of therapy, which
aims to accutely destroy tumour vasculature with a different
phenotype to normal tissues, may be even more effective than
expected if such a high proportion of the vasculature is in an
immature state. Recent demonstration of tumour regression with
growth inhibitory peptides specific for vascular endothelium was
hard to explain if only proliferating endothelial cells were inhib-
ited (Sakamoto et al, 1991). However, if over 80% of the vessels
are poorly differentiated, as a result of remodelling and endothelial
growth, inhibition of these pathways will be more effective than
previously expected.
In summary, this study has demonstrated a method for assessing
maturation of tumour-associated vessels that are poorly differenti-
ated and may therefore be involved in vascular remodelling. We
have shown that this remodelling occurs in normal premenopausal
breast but is significantly up-regulated in tumours. We also
suggest that measures of capillary maturation might be comple-
mentary to microvessel number to aid the identification of patients
who might benefit from specific anti-angiogenic therapies or
vascular targeting treatment.
REFERENCES
Almeida BM, Challacombe SJ, Eveson JW, Smith CG and Leigh IM (1992a) 
A novel lamina lucida component of epithelial and endothelial basement
membranes detected by LH39 monoclonal antibody. J Pathol 166: 243–253
Almeida BM, Challacombe SJ, Eveson JW, Morgan PR, Purkis PE and Leigh IM
(1992b) The distribution of LH39 basement membrane epitope in the tumour
stroma of oral squamous cell carcinomas. J Pathol 166: 369–374
Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ and Silverman ML (1992)
Microvessel quantitation and prognosis in invasive breast carcinoma. Hum
Pathol 23: 755–761
Bischoff J (1995) Approaches to studying cell adhesion molecules in angiogenesis.
Trends Cell Biol 5: 69–74
Blood CH and Zetter BR (1990) Tumor interactions with the vasculature:
angiogenesis and tumor metastasis. Biochim Biophys Acta 1032: 89–118
Caulin-Glazer T, Watson C, Pardi R and Bender J (1996) Efects of 17b-estradiol on
cytokine induced endothelial cell adhesion molecule expression. J Clin Invest
98: 26–42
Chalkley H (1943) Method for the quantative morphological analysis of tissues. 
J Natl Cancer Inst 4: 47–53
Deng G, Lu Y, Zlotnikof G, Thor A and Hs S (1996) Loss of heterozygosity in
normal tissue adjacent to breast carcinomas. Science 274: 2057–2059
Denton KJ, Stretch JR, Gatter KC and Harris AL (1992) A study of adhesion
molecules as markers of progression in malignant melanoma. J Pathol 167:
187–191
Folberg R, Rummelt V, Ginderdeuren R-V, Hwang T, Woolson R, Pe’er J and
Gruman L (1993) The prognostic value of tumor blood vessel morphology in
primary uveal melanoma. Ophthalmology 100: 1389–1398
Folkman J (1990) What is the evidence that tumours are angiogenesis dependent? 
J Natl Cancer Inst 82: 4–6
Folkman J (1996) What is the role of thymidine phosphorylase?
Folkman J (1997) New perspectives in clinical oncology from angiogenesis
research. Eur J Cancer 32A: 2534–2539
Fox SB (1997) Tumor angiogenesis and prognosis. Histopathology 30: 294–301
Fox SB, Gatter KC, Bicknell R, Going J, Stanton P, Cooke T and Harris AL (1993)
Relationship of endothelial cell proliferation to tumor vascularity in human
breast cancer. Cancer Res 53: 9161–9163
Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D and Harris AL (1994) The
epidermal growth factor receptor as a prognostic marker: results of 370 patients
and review of 3009 patients. Breast Cancer Res Treat 29: 41–49
Fox SB, Turner GDH, Gatter KC and Harris AL (1995a) The increased expression
of adhesion molecules ICAM-3, E and P selectin on breast endothelium. 
J Pathol 177: 369–376
Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC and Harris
AL (1995b) Platelet-derived endothelial cell growth factor/thymidine
phosphorylase expression in normal tissues: an immunohistochemical study.
J Pathol 176: 183–190
Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL (1995c)
Quantitation and prognostic value of breast cancer angiogenesis: comparison of
microvessel density, Chalkley count and computer image analysis. J Pathol
177: 275–283
Fox SB, Turner GDH, Leek RD, Whitehouse RM, Gatter KC and Harris AL (1995d)
The prognostic value of quantitative angiogenesis in breast cancer and role of
adhesion molecule expression in tumour endothelium. Breast Cancer Res Treat
36: 219–226
Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM,
Bicknell R, Gatter KC and Harris AL (1996) The angiogenic factor platelet-
derived endothelial cell growth factor/thymidine phosphorylase is up-
regulated in breast cancer epithelium and endothelium. Br J Cancer 73:
275–280
Grant DS, Kibbey MC, Kinsella JL, Cid MC and Kleinman HK (1994) The role of
basement membrane in angiogenesis and tumor growth. Pathol Res Pract 190:
854–863
Haraguchi M, Kazutaka M, Uemura K, Sumizawa T, Furukawa, Yamada K and
Akiyama S-I (1994) Angiogenic activity of enzymes. Nature 368: 198–200
Ingber D and Folkman J (1988) Inhibition of angiogenesis through modulation of
collagen metabolism. Lab Invest 59: 44–51
Kaplanski G, Farnarier C, Benoliel A, Foa C, Kaplanski S and Bongrand P (1994) 
A novel role for E- and P-selectins: shape of endothelial cell monolayers. J
Cell Sci 107: 2449–2457
Kato T, Kimura T, Ishii N, Fujii A, Yamamoto K, Kameoka S, Nishikawa T and
Kasajima T (1999) The methodology of quantitation of microvessel density
and prognostic value of neovascularization associated with long-term survival
in Japanese patients with breast cancer. Breast Cancer Res Treat 53: 19–31
Kibbey MC, Grant DS and Kleinman HK (1992) Role of the SIKVAV site of laminin
in promotion of angiogenesis and tumor growth: an in vivo Matrigel model. 
J Natl Cancer Inst 84: 1633–1638
Laurie GW and Leblond CP (1985) Basement membrane nomenclature. Nature 313:
272–274
850 S Kakolyris et al
British Journal of Cancer (2000) 82(4), 844–851 © 2000 Cancer Research CampaignLH39 as indicator of vascular maturation in breast cancer 851
British Journal of Cancer (2000) 82(4), 844–851 © 2000 Cancer Research Campaign
Lin G, Lunderquist A, Hagerstrand I and Boijsen E (1984) Postmortem examination
of the blood supply and vascular pattern of small liver metastases in man.
Surgery 96: 517–526
Luscinskas FN and Lawler J (1994) Integrins as dynamic regulators of vascular
function. FASEB J 8: 929–938
Maragoudakis ME, Sarmonika M and Panoutsakopoulou M (1988) Inhibition of
basement membrane biosynthesis prevents angiogenesis. J Pharmacol Exp
Ther 244: 729–733
Moghaddam A, Zhang H-T, Fan T-P, Hu D-E, Lees V, Turley H, Fox SB, Gatter KC,
Harris AL and Bicknell R (1995) Thymidine phosphorylase is angiogenic and
promotes tumour growth. Proc Natl Acad Sci USA 92: 988–1002
Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC,
Kleinman HK and Schnaper HW (1995) Estrogen promotes angiogenic activity
in human umbilical vein endothelial cells in vitro and in a murine model.
Circulation 91: 755–763
Nelson H, Ramsey P, Donohue J and Wold L (1994) Cell adhesion molecule
expression within the microvasculature of human colorectal malignancies. Clin
Immunol Immunopathol 72: 129–136
Nguyen M, Strubel NA and Bischoff J (1993) A role for sialyl Lewis-X/A
glycoconjugates in capillary morphogenesis. Nature 365: 267–269
Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF and Folkman J (1994)
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the
urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:
356–361
Nicosia RF and Bonanno E (1991) Inhibition of angiogenesis in vitro by Arg-Gly-
Asp-containing synthetic peptide. Am J Pathol 138: 829–833
Orlidge A and D’Amore PA (1987) Inhibition of capillary endothelial cell growth by
pericytes and smooth muscle cells. J Cell Biol 105: 1455–1462
Paku S and Paweletz N (1991) First steps of tumor-related angiogenesis. Lab Invest
65: 334–346
Paweletz N and Knierim M (1989) Tumor-related angiogenesis. Crit Rev Oncol
Hematol 9: 197–242
Pezella F, Dibacco A, Andreola S, Nicholson AG, Pastorino U and Harris AL (1996)
Angiogenesis in primary lung-cancer and lung secondaries. Eur J Cancer 32A:
2494–2500
Sakamoto N, Iwahana M, Tanaka NG and Osada Y (1991) Inhibition of
angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-
NH2. Cancer Res 51: 903–906
Schnaper H, McGowan K, Kim-Schulze S and Cid M (1996) Oestrogen and
endothelial cell angiogenic activity. Clin Exp Pharmacol Physiol 23: 247–250
Sholley M, Ferguson G, Hr S, Montour J and Wilson J (1984) Mechanisms of
neovascularization; vascular sprouting can occur without proliferation of
endothelial cells. Lab Invest 51: 624–634
Skinner SA, Frydman GM and O’Brien PE (1995) Microvascular structure of benign
and malignant tumours of the colon in humans. Dig Dis Sci 40: 373–384
Toi M, Hoshina S, Takayanagi T and Tominaga T (1994) Association of vascular
endothelial growth factor expression with tumor angiogenesis and with early
relapse in primary breast cancer. Jpn J Cancer Res 85: 1045–1049
Van Hoef MEHM, Knox WF, Dhesi SS, Howell A and Schor AM (1993)
Assessment of tumour vascularity as a prognostic factor in lymph node
negative invasive breast cancer. Eur J Cancer 29: 1141–1145
Vartanian RK and Weidner N (1994) Correlation of intratumoral endothelial-cell
proliferation with microvessel density (tumor angiogenesis) and tumor-cell
proliferation in breast-carcinoma. Am J Pathol 144: 1188–1194
Warren B (1997) The vascular morphology of tumors. In: Tumor Blood Circulation,
Peterson H (ed), pp. 1–47. CRC Press: Boca Raton
Weidner N, Semple JP, Welch WR and Folkman J (1991) Tumour angiogenesis
and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:
1–8
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S and
Gasparini G (1992) Tumor angiogenesis: a new significant and independent
prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:
1875–1887